Back

Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients: a subgroup analysis of age

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Pulmonary circulation, pulmonary embolism, right heart failure e-posters Venous Thromboembolism ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Ms Janvi Sah

Ann Arbor (United States of America)

73 More presentations in this session

Presentation thumbnail
The novel noninvasive method for prediction of long-term specific therapy efficacy in patients with IPAH and inoperable CTEPH
Mrs I. Lyapina (Kemerovo, RU)
Abstract Slides
Presentation thumbnail
Early and long term prognostic accuracy of 4 acute pulmonary embolism mortality risk scores
Doctor L. Oliveira (Ponta Delgada, PT)
Abstract Slides
Presentation thumbnail
Novel genetic and molecular pathways in pulmonary arterial hypertension associated with connective tissue disease
Doctor I. Hernandez Gonzalez (Valladolid, ES)
Abstract Slides
Presentation thumbnail
Role of echocardiography to avoid misclassification of pulmonary hypertension associated with left heart disease as precapillary pulmonary hypertension.
Assistant Professor J. Grignola Rial (Montevideo, UY)
Abstract Slides
Presentation thumbnail
Survival of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension listed for lung transplantation
Doctor I. Magnani (Bologna, IT)
Abstract

Access the full session

Session thumbnail
Pulmonary circulation, pulmonary embolism, right heart failure e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
31 August 2020
thumbnail
Congress Presentation
Safety and effectiveness of ultrasound assisted catheter-directed thrombolysis for acute intermediate-high and high risk pulmonary embolism: all eyes on elderly
20 March 2026
thumbnail
Congress Presentation
Comparison of apixaban 5 mg vs 2.5 mg for the prevention of cancer-associated venous thromboembolism: A pooled analysis of two studies
21 June 2025
thumbnail
Congress Presentation
Prescription pattern of evidence-based pharmacotherapy in heart failure: An age perspective
15 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources